Supplementary Table 2. Least squares mean differences (vs. placebo) in LDL-C and secondary lipid parameters in patients of alirocumab group in modified intent-to-treat population

Lipid parameter	% Change at week 24 from baseline		Difference of % change compared to placebo group	95% CI	p value
	Placebo (n = 43)	Alirocumab (n = 40)			
LDL-C	11.1 ± 4.2	−67.3 ± 4.4	−78.5 ± 6.1	−90.6 to −66.3	< 0.0001
non-HDL-C	8.2 ± 3.1	−55.9 ± 3.2	−64.1 ± 4.4	−72.9 to −55.3	< 0.0001
HDL-C	8.1 ± 2.9	16.9 ± 3.0	8.7 ± 4.2	0.4 to 17.1	0.0412
Fasting TG	−0.05 ± 4.9	−8.3 ± 5.0	−8.3 ± 7.0	−22.0 to 5.3	0.2298
TC	7.1 ± 2.3	−35.9 ± 2.4	−43.0 ± 3.3	−49.7 to −36.4	< 0.0001
Lp(a)	5.3 ± 5.7	−37.0 ± 5.6	−42.3 ± 8.0	−58.0 to −26.6	< 0.0001
Apo A1	7.2 ± 2.1	3.7 ± 2.2	−3.5 ± 3.0	−9.6 to 2.5	0.2482
Apo B	7.9 ± 3.1	−50.4 ± 3.2	−58.2 ± 4.5	−67.2 to −49.2	< 0.0001

Values are presented as mean ± SE.

LDL-C, low density lipoprotein cholesterol; CI, confidence interval; HDL-C, high density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; Lp(a), lipoprotein(a); Apo A1, apolipoprotein A1; Apo B, apolipoprotein B.